Lytix Biopharma is a clinical-stage company committed to developing novel immunotherapy for cancer patients. The aim is to become a leader within immunotherapy of solid tumors.

Lytix Biopharma’s development program focuses on immunological activation of solid tumors such as breast cancer, malignant melanoma, sarcoma, head & neck, and other. The mode of action is to release antigens and reshape the tumor microenvironment and as such turning cold tumors hot.

The strategy is to develop the oncolytic peptides within several tumor type indications, and also explore several therapeutic settings such as combination therapies and T-cell therapies.

For more information, please email us at: post@lytixbiopharma.com


Top 20 shareholders of Lytix Biopharma AS - as of 1 June 2017
Shareholder Number of shares % of shares +/- shares
last month
North Murray AS* 189 504 15.8  
Picasso Kapital AS* 109 786 9.2  
TAJ Holding AS 97 081 8.1  
CARE Holding AS 75 093 6.3  
Norinnova Invest AS 45 116 3.8  
Lysnes Invest AS 40 675 3.4  
3 T PRODUKTER 35 268 2.9  
LMK Venture AB 34 600 2.9  
Hopen Invest AS 28 314 2.4  
Kreftforeningen 21 800 1.8  
Per Strand Eiendom AS 19 635 1.6  
Mikael Lönn 17 300 1.4  
Rothesay Limited 17 300 1.4  
4LB INVEST AS 16 004 1.3  
Nordinnova Technology Transfer AS 15 579 1.3  
John Sigurd Svendsen* 15 242 1.3  
Sparebank1 Nord-Norge Portefølje AS 15 182 1.3  
Jahatt AS 14 364 1.2  
Innovasjon Norge AS 13 379 1.1  
Jesem AS 10 967 0.9  
Other shareholders 363 561 30.4  
Total 1 195 750
100.0  

*Companies where members of the board and/or management of Lytix Biopharma AS are represented.

 

Trades among insiders of Lytix Biopharma AS last month:
(I = Share issue, SO = Share Options)

 

* List of insiders within the Board and Management
Lytix Biopharma Board Lytix Biopharma Management
Gert Munthe, Chairman Edwin Klumper, CEO
Knut Eidissen, member Håkan Wickholm, CBO
Kari Grønås, member Øystein Rekdal, Co-founder and CSO
John Sigurd Svendsen, member Wenche Marie Olsen, COO
Lena Torlegård, member Andrew Saunders, CMO
Morten Jurs, member Torbjørn Furuseth, CFO
Debasish Roychowdhury, member